About Us

At Ironshore Pharmaceuticals & Development, Inc. we use proprietary drug-delivery technology to develop improved versions of existing drug products.

What We Do

Ironshore Pharmaceuticals & Development, Inc. is a biopharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing its proprietary DELEXIS® technology, to improve the lives of patients and caregivers. Based in Grand Cayman, Ironshore is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore Pharmaceuticals Inc., based in Philadelphia, PA, is responsible for the sales, marketing and distribution of Ironshore’s products within the US. Both companies are wholly owned subsidiaries of Toronto-based Highland Therapeutics Inc.

Ironshore's lead compound, HLD200 (delayed-release and extended-release methylphenidate) is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application for HLD200 is currently being reviewed by the U.S. Food and Drug Administration.

HLD100, also under development for the treatment of ADHD, is expected to begin a pivotal Phase 3 trial in H2/2017.

Ironshore Offices

Early Morning Functioning

Ironshore in the United States

US Head Office
1550 Liberty Ridge Dr.
Suite 300
Chesterbrook, PA 19087-5567
United States

Main phone: 484-222-4930

Controlled Release

Ironshore in the Cayman Islands

Research & Development Headquarters
10 Market Street
Suite 715
Camana Bay, KY1-9006
Cayman Islands

Highland Therapeutics

Highland Therapeutics Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary drugs utilizing a proprietary drug delivery system named DELEXIS®. Visit to learn more.

Highland's Main Office

Highland Office

Highland Pharmaceuticals

MaRS Centre Heritage Building
101 College St, Suite HL20-2
Toronto, ON Canada M5G 1L7